Sweeney, N. J. et al. The Escherichia coli K-12 gntP gene allows E. coli F-18 to occupy a distinct nutritional niche in the streptomycin-treated mouse large intestine. Infect. Immun. 64, 34973503 (1996).
Nataro, J. P. & Kaper, J. B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11, 142201 (1998). A comprehensive review of the pathogenesis, epidemiology, diagnosis and clinical aspects of diarrhoeagenic E. coli.
Russo, T. A. & Johnson, J. R. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J. Infect. Dis. 181, 17531754 (2000).
Whittam, T. S. in Escherichia coli and Salmonella (eds Neidhardt, F. C. et al.) 27082720 (ASM Press, Washington DC, USA, 1996).
Cassels, F. J. & Wolf, M. K. Colonization factors of diarrheagenic E. coli and their intestinal receptors. J. Ind. Microbiol. 15, 214226 (1995).
Keller, R. et al. Afa, a diffuse adherence fibrillar adhesin associated with enteropathogenic Escherichia coli. Infect. Immun. 70, 26812689 (2002).
Tieng, V. et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc. Natl Acad. Sci. USA 99, 29772982 (2002).
Goldberg, M. B. & Theriot, J. A. Shigella flexneri surface protein IcsA is sufficient to direct actin-based motility. Proc. Natl Acad. Sci. USA 92, 65726576 (1995).
Tapping, R. I., Akashi, S., Miyake, K., Godowski, P. J. & Tobias, P. S. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol. 165, 57805787 (2000).
Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 10991103 (2001).
Sears, C. L. & Kaper, J. B. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol. Rev. 60, 167215 (1996).
Melton-Celsa, A. R. & O'Brien, A. D. in Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains (eds Kaper, J. B. & O'Brien, A. D.) 121128 (ASM Press, Washington DC, USA, 1998).
De Rycke, J. & Oswald, E. Cytolethal distending toxin (CDT): a bacterial weapon to control host cell proliferation? FEMS Microbiol Lett. 203, 141148 (2001).
Marches, O. et al. Enteropathogenic and enterohaemorrhagic Eschericha coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. Mol. Microbiol 50, 15531567 (2003).
Lerm, M. et al. Deamidation of Cdc42 and Rac by Escherichia coli cytotoxic necrotizing factor 1: activation of c-Jun N-terminal kinase in HeLa cells. Infect. Immun. 67, 496503 (1999).
Kenny, B. et al. Co-ordinate regulation of distinct host cell signalling pathways by multifunctional enteropathogenic Escherichia coli effector molecules. Mol. Microbiol. 44, 10951107 (2002).
Tauschek, M., Gorrell, R. J., Strugnell, R. A. & Robins-Browne, R. M. Identification of a protein secretory pathway for the secretion of heat-labile enterotoxin by an enterotoxigenic strain of Escherichia coli. Proc. Natl Acad. Sci. USA 99, 70667071 (2002).
Henderson, I. R., Navarro-Garcia, F. & Nataro, J. P. The great escape: structure and function of the autotransporter proteins. Trends Microbiol. 6, 370378 (1998).
Hueck, C. J. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol. Mol. Biol. Rev. 62, 379433 (1998).
Balakrishnan, L., Hughes, C. & Koronakis, V. Substrate-triggered recruitment of the TolC channel-tunnel during type I export of hemolysin by Escherichia coli. J. Mol. Biol. 313, 501510 (2001).
McDaniel, T. K., Jarvis, K. G., Donnenberg, M. S. & Kaper, J. B. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc. Natl Acad. Sci. USA 92, 16641668 (1995). The first description of a pathogenicity island in enteric E. coli pathotypes.
Jerse, A. E., Yu, J., Tall, B. D. & Kaper, J. B. A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc. Natl Acad. Sci. USA 87, 78397843 (1990).
Higgins, L. M. et al. Role of bacterial intimin in colonic hyperplasia and inflammation. Science 285, 588591 (1999).
Kenny, B. et al. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 91, 511520 (1997). The first report of a bacterium translocating its receptor into mammalian cells by a type III secretion system.
Muza-Moons, M. M., Koutsouris, A. & Hecht, G. Disruption of cell polarity by enteropathogenic Escherichia coli enables basolateral membrane proteins to migrate apically and to potentiate physiological consequences. Infect. Immun. 71, 70697078 (2003).
Sinclair, J. F. & O'Brien, A. D. Cell surface-localized nucleolin is a eukaryotic receptor for the adhesin intimin- of enterohemorrhagic Escherichia coli O157:H7. J. Biol. Chem. 277, 28762885 (2002).
Kalman, D. et al. Enteropathogenic E. coli acts through WASP and Arp2/3 complex to form actin pedestals. Nature Cell Biol. 1, 389391 (1999).
Campellone, K. G. & Leong, J. M. Tails of two Tirs: actin pedestal formation by enteropathogenic E. coli and enterohemorrhagic E. coli O157:H7. Curr. Opin. Microbiol. 6, 8290 (2003).
Vallance, B. A. & Finlay, B. B. Exploitation of host cells by enteropathogenic Escherichia coli. Proc. Natl Acad. Sci. USA 97, 87998806 (2000).
Sanger, J. M., Chang, R., Ashton, F., Kaper, J. B. & Sanger, J. W. Novel form of actin-based motility transports bacteria on the surface of infected cells. Cell Motil. Cytoskeleton 34, 279287 (1996).
Crane, J. K., McNamara, B. P. & Donnenberg, M. S. Role of EspF in host cell death induced by enteropathogenic Escherichia coli. Cell Microbiol. 3, 197211 (2001).
McNamara, B. P. et al. Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J. Clin. Invest. 107, 621629 (2001).
Klapproth, J. M. et al. A large toxin from pathogenic Escherichia coli strains that inhibits lymphocyte activation. Infect. Immun. 68, 21482155 (2000).
Nicholls, L., Grant, T. H. & Robins-Browne, R. M. Identification of a novel genetic locus that is required for in vitro adhesion of a clinical isolate of enterohaemorrhagic Escherichia coli to epithelial cells. Mol. Microbiol. 35, 275288 (2000).
Tobe, T. et al. Complete DNA sequence and structural analysis of the enteropathogenic Escherichia coli adherence factor plasmid. Infect. Immun. 67, 54555462 (1999).
Girn, J. A., Ho, A. S. Y. & Schoolnik, G. K. An inducible bundle-forming pilus of enteropathogenic Escherichia coli. Science 254, 710713 (1991).
Trabulsi, L. R., Keller, R. & Tardelli Gomes, T. A. Typical and atypical enteropathogenic Escherichia coli. Emerg. Infect. Dis. 8, 508513 (2002).
Hecht, G. Microbes and microbial toxins: paradigms for microbialmucosal interactions. VII. Enteropathogenic Escherichia coli: physiological alterations from an extracellular position. Am. J. Physiol Gastrointest. Liver Physiol. 281, G1G7 (2001).
Frankel, G. et al. Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol. Microbiol. 30, 911921 (1998).
Kenny, B. Mechanism of action of EPEC type III effector molecules. Int. J. Med. Microbiol. 291, 469477 (2002).
Hecht, G. et al. Pathogenic Escherichia coli increase Cl secretion from intestinal epithelia by upregulating galanin-1 receptor expression. J. Clin. Invest. 104, 253262 (1999).
Varma, J. K. et al. An outbreak of Escherichia coli O157 infection following exposure to a contaminated building. JAMA 290, 27092712 (2003).
Andreoli, S. P., Trachtman, H., Acheson, D. W., Siegler, R. L. & Obrig, T. G. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr. Nephrol. 17, 293298 (2002).
Jones, N. L. et al. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G811G819 (2000).
Reid, S. D., Herbelin, C. J., Bumbaugh, A. C., Selander, R. K. & Whittam, T. S. Parallel evolution of virulence in pathogenic Escherichia coli. Nature 406, 6467 (2000).
Tatsuno, I. et al. toxB gene on pO157 of enterohemorrhagic Escherichia coli O157:H7 is required for full epithelial cell adherence phenotype. Infect. Immun. 69, 66606669 (2001).
Burland, V. et al. The complete DNA sequence and analysis of the large virulence plasmid of Escherichia coli O157:H7. Nucleic Acids Res. 26, 41964204 (1998).
Lathem, W. W. et al. StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Mol. Microbiol. 45, 277288 (2002).
Perna, N. T. et al. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 409, 529533 (2001). The first reported genome sequence for a pathogenic E. coli strain.
Heimer, S. R. et al. Urease of enterohemorrhagic Escherichia coli: evidence for regulation by fur and a trans-acting factor. Infect. Immun. 70, 10271031 (2002).
Wolf, M. K. Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli. Clin. Microbiol. Rev. 10, 569584 (1997).
Spangler, B. D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56, 622647 (1992).
Pizza, M. et al. Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 25342541 (2001).
Currie, M. G. et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc. Natl Acad. Sci. USA 89, 947951 (1992). This paper suggests that STa evolved as a molecular mimic of an endogenous ligand. This model is necessary, not only to understand ETEC pathogenesis and evolution, but also to provide a context for future studies of microbial evolution.
Dubreuil, J. D. Escherichia coli STb enterotoxin. Microbiology 143, 17831795 (1997).
Pitari, G. M. et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl Acad. Sci. USA 100, 26952699 (2003).
Nataro, J. P., Steiner, T. S. & Guerrant, R. L. Enteroaggregative Escherichia coli. Emerg. Infect. Dis. 4, 251261 (1998).
Hicks, S., Candy, D. C. A. & Phillips, A. D. Adhesion of enteroaggregative Escherichia coli to pediatric intestinal mucosa in vitro. Infect. Immun. 64, 47514760 (1996).
Vial, P. A. et al. Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J. Infect. Dis. 158, 7079 (1988).
Benjamin, P., Federman, M. & Wanke, C. A. Characterization of an invasive phenotype associated with enteroaggregative Escherichia coli. Infect. Immun. 63, 34173421 (1995).
Abe, C. M., Knutton, S., Pedroso, M. Z., Freymuller, E. & Gomes, T. A. An enteroaggregative Escherichia coli strain of serotype O111:H12 damages and invades cultured T84 cells and human colonic mucosa. FEMS Microbiol. Lett. 203, 199205 (2001).
Czeczulin, J. R. et al. Aggregative adherence fimbria II, a second fimbrial antigen mediating aggregative adherence in enteroaggregative Escherichia coli. Infect. Immun. 65, 41354145 (1997).
Nataro, J. P. et al. Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect. Immun. 60, 22972304 (1992).
Nataro, J. P., Yikang, D., Yingkang, D. & Walker, K. AggR, a transcriptional activator of aggregative adherence fimbria I expression in enteroaggregative Escherichia coli. J. Bacteriol. 176, 46914699 (1994). Describes the emergence of AggR as a global regulator of virulence genes in EAEC
Sheikh, J. et al. A novel dispersin protein in enteroaggregative Escherichia coli. J. Clin. Invest. 110, 13291337 (2002).
Steiner, T. S., Nataro, J. P., Poteet-Smith, C. E., Smith, J. A. & Guerrant, R. L. Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J. Clin. Invest 105, 17691777 (2000). The pathogenesis of EAEC is not completely understood, but inflammation might be an important component.
Henderson, I. R., Czeczulin, J., Eslava, C., Noriega, F. & Nataro, J. P. Characterization of Pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. Infect. Immun. 67, 55875596 (1999).
Noriega, F. R., Liao, F. M., Formal, S. B., Fasano, A. & Levine, M. M. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J. Infect. Dis. 172, 14081410 (1995).
Savarino, S. J. et al. Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc. Natl Acad. Sci. USA 90, 30933097 (1993).
Menard, L. P. & Dubreuil, J. D. Enteroaggregative Escherichia coli heat-stable enterotoxin 1 (EAST1): a new toxin with an old twist. Crit. Rev. Microbiol. 28, 4360 (2002).
Navarro-Garcia, F. et al. In vitro effects of a high-molecular weight heat-labile enterotoxin from enteroaggregative Escherichia coli. Infect. Immun. 66, 31493154 (1998).
Jiang, Z. D., Greenberg, D., Nataro, J. P., Steffen, R. & DuPont, H. L. Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J. Clin. Microbiol. 40, 41854190 (2002).
Wei, J. et al. Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect. Immun. 71, 27752786 (2003).
Pupo, G. M., Lan, R. & Reeves, P. R. Multiple independent origins of Shigella clones of Escherichia coli and convergent evolution of many of their characteristics. Proc. Natl Acad. Sci. USA 97, 1056710572 (2000). This paper suggests that Shigella should be considered within the species Escherichia coli , and that their evolution represents adaptation to a specific pathogenetic niche, a phenomenon that has occurred on several occasions over many years.
Sansonetti, P. Hostpathogen interactions: the seduction of molecular cross talk. Gut 50, Suppl. 3 S2S8 (2002).
Zychlinsky, A., Prevost, M. C. & Sansonetti, P. J. Shigella flexneri induces apoptosis in infected macrophages. Nature 358, 167169 (1992).
Buchrieser, C. et al. The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri. Mol. Microbiol. 38, 760771 (2000).
Egile, C. et al. Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin- based motility. J. Cell Biol. 146, 13191332 (1999).
Sansonetti, P. J. et al. Caspase-1 activation of IL-1 and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity. 12, 581590 (2000). The pathogenesis of Shigella infection represents a complex manipulation of the immune response, in ways that are beneficial to both pathogen and host.
Tran Van Nhieu, G., Bourdet-Sicard, R., Dumenil, G., Blocker, A. & Sansonetti, P. J. Bacterial signals and cell responses during Shigella entry into epithelial cells. Cell. Microbiol. 2, 187193 (2000).
Niebuhr, K. et al. Conversion of PtdIns(4,5)P2 into PtdIns5P by the S. flexneri effector IpgD reorganizes host cell morphology. EMBO J. 21, 50695078 (2002).
Scaletsky, I. C. et al. Diffusely adherent Escherichia coli as a cause of acute diarrhea in young children in northeast Brazil: a case-control study. J. Clin. Microbiol. 40, 645648 (2002).
Bilge, S. S., Clausen, C. R., Lau, W. & Moseley, S. L. Molecular characterization of a fimbrial adhesin, F1845, mediating diffuse adherence of diarrhea-associated Escherichia coli to HEp-2 cells. J. Bacteriol. 171, 42814289 (1989).
Hasan, R. J. et al. Structurefunction analysis of decayaccelerating factor: identification of residues important for binding of the Escherichia coli Dr adhesin and complement regulation. Infect. Immun. 70, 44854493 (2002).
Bernet-Camard, M. F., Coconnier, M. H., Hudault, S. & Servin, A. L. Pathogenicity of the diffusely adhering strain Escherichia coli C1845: F1845 adhesin-decay accelerating factor interaction, brush border microvillus injury, and actin disassembly in cultured human intestinal epithelial cells. Infect. Immun. 64, 19181928 (1996).
Peiffer, I., Servin, A. L. & Bernet-Camard, M. F. Piracy of decay-accelerating factor (CD55) signal transduction by the diffusely adhering strain Escherichia coli C1845 promotes cytoskeletal F-actin rearrangements in cultured human intestinal INT407 cells. Infect. Immun. 66, 40364042 (1998). DAEC exhibits a unique pathogenetic scheme that includes cytoskeletal sabotage.
Peiffer, I., Bernet-Camard, M. F., Rousset, M. & Servin, A. L. Impairments in enzyme activity and biosynthesis of brush border-associated hydrolases in human intestinal Caco-2/TC7 cells infected by members of the Afa/Dr family of diffusely adhering Escherichia coli. Cell. Microbiol. 3, 341357 (2001).
Phillips, I. et al. Epidemic multiresistant Escherichia coli infection in West Lambeth Health District. Lancet 1, 10381041 (1988).
Manges, A. R. et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N. Engl. J. Med. 345, 10071013 (2001). This work identified specific clonal groups of E. coli that cause widespread antibiotic resistant bacteria.
Nowicki, B., Svanborg-Eden, C., Hull, R. & Hull, S. Molecular analysis and epidemiology of the Dr hemagglutinin of uropathogenic Escherichia coli. Infect. Immun. 57, 446451 (1989).
Johnson, J. R. Virulence factors in Escherichia coli urinary tract infection. Clin. Microbiol. Rev. 4, 80128 (1991).
Johnson, J. R. & Stell, A. L. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. 181, 261272 (2000).
Welch, R. A. et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc. Natl Acad. Sci. USA 99, 1702017024 (2002). The first complete nucleotide sequence of a representative uropathogenic strain of E. coli and shows that EHEC, UPEC and E. coli K-12 share only 39.2% of the combined set of predicted proteins.
Bahrani-Mougeot, F. K. et al. Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract. Mol. Microbiol. 45, 10791093 (2002).
Gunther, N. W., Lockatell, V., Johnson, D. E. & Mobley, H. L. In vivo dynamics of type 1 fimbria regulation in uropathogenic Escherichia coli during experimental urinary tract infection. Infect. Immun. 69, 28382846 (2001).
Connell, I. et al. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc. Natl Acad. Sci. USA 93, 98279832 (1996). Demonstrates that type 1 fimbriae satisfies molecular Koch's postulates.
Mulvey, M. A. et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282, 14941497 (1998).
Anderson, G. G. et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301, 105107 (2003).
Svanborg-Eden, C. & Hansson, H. A. Escherichia coli pili as possible mediators of attachment to human urinary tract epithelial cells. Infect. Immun. 21, 229237 (1978).
Korhonen, T. K., Virkola, R. & Holthofer, H. Localization of binding sites for purified Escherichia coli P fimbriae in the human kidney. Infect. Immun. 54, 328332 (1986).
Continue reading here:
Pathogenic Escherichia coli | Nature Reviews Microbiology
- Stem Cell Manufacturing Market 2021 | Research With Size, Growth, Manufacturers, Key Segment, Analysis, Development Status, Segments and 2027... - February 19th, 2021
- Tissue regeneration: Reserve or reverse? - Science Magazine - February 19th, 2021
- Global Scaffold Technology Market Is Expected to Reach USD 2.16 billion by 2028 : Fior Markets - GlobeNewswire - February 19th, 2021
- Recombinant Growth Factors to Account for Over 45% of Overall Demand through 2031: Persistence Market Research - PRNewswire - February 19th, 2021
- The Untapped Potential of Cell and Gene Therapy - AJMC.com Managed Markets Network - February 19th, 2021
- Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey -... - February 19th, 2021
- Cell Therapy Processing Market To Grow Value $12062 Million By 2026 | Latest Research Report - PharmiWeb.com - February 19th, 2021
- Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel... - February 19th, 2021
- Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market - BioSpace - February 19th, 2021
- Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PRNewswire - February 19th, 2021
- Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,... - February 19th, 2021
- Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer... - February 19th, 2021
- Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,... - February 19th, 2021
- How Irish medtech came to thrive - Med-Tech Innovation - February 19th, 2021
- Translational Regenerative Medicine Market: Immunotherapy is projected to be the fastest growing segment during the forecast period - BioSpace - February 11th, 2021
- Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First Off-the-shelf Genomic Medicines - Business Wire - February 11th, 2021
- Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies - PRNewswire - February 11th, 2021
- Global Biopreservation Market Is Expected to Reach USD 7.67 Billion by 2028 : Fior Markets - GlobeNewswire - February 11th, 2021
- Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater... - February 11th, 2021
- Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi... - February 11th, 2021
- 2020 Outlook on the Global Singlecell Technology Industry - Market Size was Over $800 Million in 2019 - ResearchAndMarkets.com - Business Wire - February 11th, 2021
- Stem Cell Cryopreservation Equipments Market Size Report: Strategies of Key Manufacturers, Project Investment of New Industries: Chart, Worthington... - February 11th, 2021
- Seattle Cancer Care Alliance Celebrates 20 Years of Innovation in Cancer Treatment and Care - Business Wire - February 11th, 2021
- Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire - February 11th, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- Biobanking Market Report Research and Global Outlook 2021 to 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - February 7th, 2021
- Animal Stem Cell Therapy Market By Product Type (Dogs, Horses) And By End-Users/Application (Veterinary Hospitals, Research Organizations) Market... - February 6th, 2021
- Stem Cell Assay Market Share, Demand, Manufacturers and Forecast till 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent... - February 6th, 2021
- Global Apoptosis Assays Market Set To Grow At Healthy CAGR Of 11.10% By 2027||Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG, Biotium,... - February 6th, 2021
- Jill Biden signals White House resolve on cancer research: This is the fight of our lives - The Cancer Letter - February 6th, 2021
- Tiny sensor technique reveals cellular forces involved in tissue generation - Brown University - February 6th, 2021
- Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,... - February 6th, 2021
- Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer - OncLive - February 6th, 2021
- Stem Cell Market is Expected to Grow with an Impressive CAGR till 2027 | Players Vcanbio, Boyalife, Beikebiotech KSU | The Sentinel Newspaper - KSU... - February 6th, 2021
- Regenerative Medicine Market to be Valued at USD 6.49 Billion by 2027 | The Escalating Burden of Chronic Diseases and Genetic Aberrations will be the... - February 4th, 2021
- Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology - PRNewswire - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - Yahoo Finance UK - February 4th, 2021
- Biobanks Market | Prominent Factors Analysis that will Help in Reshaping the Market Growth - BioSpace - February 4th, 2021
- Alexion Reports Fourth Quarter and Full Year 2020 Results - BioSpace - February 4th, 2021
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Size, Share, Analysis, Growth Driver and Industry Segments by 2027 KSU | The... - February 4th, 2021
- Transfection Technologies Market Size 2020 | Global Business Strategies, Growing CAGR of 20.0%, Industry Revenue, Opportunities-Aldrich Co Thermo... - February 4th, 2021
- Global Apoptosis Assays Market Report 2020: Apoptosis Assay Kits Lead the Demand with 42.5% Share - Forecast to 2026 - GlobeNewswire - February 4th, 2021
- Global Hematopoietic Stem Cells Transplantation Market 2020 Industry Scenario, Strategies, Growth Factors and Forecast to 2025 KSU | The Sentinel... - February 4th, 2021
- Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID) - GlobeNewswire - February 4th, 2021
- Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell... - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Adipose Tissue-Derived Stem Cells (ADSCS) Market is Projected to Grow Massively in Near Future The Courier - The Courier - February 4th, 2021
- Healthcare Inventory Management Market: Rising Research and Development is Anticipated to Drive the Market - BioSpace - January 30th, 2021
- Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing - Labiotech.eu - January 30th, 2021
- Latest Research and Industry Trends of Cell and Tissue Culture Supplies Market Forecast 2027 Stemcell Technologies, Wheaton Industries, GE Healthcare ... - January 30th, 2021
- 5 People in the BioHealth Capital Region You Should Know In 2021 - BioBuzz - January 30th, 2021
- Global CAR-T Therapy Market Opportunities and Strategies Report 2020: COVID-19 Impact and Recovery - Forecast to 2030 - GlobeNewswire - January 30th, 2021
- Their Goal: Meat That's Better Than Meat | Tufts Now - Tufts Now - January 30th, 2021
- Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab -... - January 30th, 2021
- Cell and Gene Therapy Market Size to Reach USD 7,250.0 Million by 2028 | Increasing Investments in Production Capacity Expansion for Cell and Gene... - January 30th, 2021
- Protein identified that may help treat Parkinsons disease - Medical News Today - January 30th, 2021
- Human physiomimetic model integrating microphysiological systems of the gut, liver, and brain for studies of neurodegenerative diseases - Science... - January 30th, 2021
- Elevian Targets Aging to Solve Humanity's Toughest Diseases - BioSpace - January 30th, 2021
- Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment - Business Wire - January 30th, 2021
- Global Stem Cell Reconstructive Market Detailed analysis of current Industry figures with forecasts growth by 2028 | Top Players; Osiris... - January 25th, 2021
- Cell Separation Technologies Market to Reach $28.76 Bn, Globally, by 2027 at 15.4% CAGR, Says Allied Market Research - PRNewswire - January 25th, 2021
- Stem Cell Therapy Market to Witness Increase in Revenues by 2025 NeighborWebSJ - NeighborWebSJ - January 25th, 2021
- Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - BioSpace - January 23rd, 2021
- Comprehensive Report on Stem Cell Banking Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 |Cordlife, Cryo-Cell... - January 23rd, 2021
- Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism... - January 22nd, 2021
- BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn Derived Exosome-Based Treatment for COVID-19 ARDS -... - January 22nd, 2021
- Regenerative medicine is advancing health care in diverse ways - Hometown Focus - January 22nd, 2021
- Gene Pathway Linked to Development of Schizophrenia - Psychiatric Times - January 22nd, 2021
- Humanigen Announces the Addition of BARDA and Expansion of CRADA with the US Government to Develop Lenzilumab for COVID-19 - BioSpace - January 22nd, 2021
- Cell Sorting Market Size to Reach USD 805.1 Million By 2027 | Expanding Biotechnology And Pharmaceutical Industries will be the Major Factor Driving... - January 22nd, 2021
- BrainStorm's Covid-19 ARDS treatment improves lung function in study - Clinical Trials Arena - January 22nd, 2021
- Impact of Covid-19 on Automated Cell Culture Market Influencing the Industry Development and Forecast | BD, Tecan Trading, Sartorius, TAP Biosystems,... - January 22nd, 2021
- Global Live Cell Imaging Market Size is Expected to reach USD 3529.26 Million by 2025 and Registeri - PharmiWeb.com - January 22nd, 2021
- [Full text] Identification and Targeting of ThomsenFriedenreich and IL1RAP | OTT - Dove Medical Press - January 22nd, 2021
- New Genetic Disorder Discovered That Affects Brain and Craniofacial Skeleton - Technology Networks - January 22nd, 2021
- Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology - PRNewswire - January 22nd, 2021
- Stem cells on the ballot - Science Magazine - January 14th, 2021
- 2021 Startups to Watch: Ronawk's T-Blocks stack the future of stem cell research in an Olathe lab - Startland News - January 14th, 2021
- Towards a Cure: Carleton Research Team Working on Stem Cell Therapy to Reverse Type 1 Diabetes - Carleton Newsroom - January 14th, 2021
- Stem Cell Assay Market | Know the aspects that will serve as game-changers for the market - BioSpace - January 14th, 2021